Kymera Therapeutics filings document the regulatory record of a Nasdaq-listed clinical-stage biotechnology company developing oral small molecule degraders through targeted protein degradation. Its Form 8-K reports cover material events such as operating and financial results, clinical and regulatory disclosures, Regulation FD presentations, collaboration-related updates, and capital-raising arrangements involving common stock.
Proxy and governance filings describe shareholder voting matters, executive compensation, equity awards, board oversight, and bylaw provisions, including forum-selection language. The filing record also identifies KYMR common stock and recurring disclosure areas tied to the company’s pipeline, financing capacity, corporate governance, and public-company reporting obligations.
KYMR notice reports a proposed transaction and recent affiliate sales. The filing lists an exercise of stock options resulting in 2,500 shares to be sold on 06/22/2026 for cash. It also discloses prior 10b5-1 sales by Noah Goodman on 04/09/2026 (5,764 shares, $500,582.20), 04/09/2026 (2,500 shares, $222,500.00), 04/10/2026 (2,000 shares, $174,700.00), and 04/14/2026 (1,347 shares, $121,230.00).
KYMR affiliates reported proposed sales of Common Stock on Form 144. The notice lists multiple dispositions by Atlas Venture entities and by Bruce Booth on 04/15/2026, 04/22/2026, and 06/18/2026
Examples include Atlas Venture Fund X, L.P. proposing a sale of 92,169 shares on 06/18/2026 for $8,330,667.41, and Bruce Booth reporting 11,741 shares on 06/18/2026 for $1,056,443.24. The transactions are reported as resale of previously acquired common stock from a private placement.
KYMR affiliate sales reported under Rule 144. The excerpt lists multiple sales of Common Stock by affiliated holders and individuals, including transactions on 04/15/2026, 04/22/2026, and 06/18/2026. Reported sellers include Atlas Venture Fund X, L.P., Atlas Venture Opportunity Fund I, L.P., and Bruce Booth. Sales are shown with share counts and gross proceeds per line.
KYMR reported proposed dispositions of Common Stock under Form 144 by certain holders, listing specific sale dates and share counts. The filing lists multiple reported sales in April 2026, including 2,750 shares on 04/15/2026 and 5,900 shares on 04/22/2026 by identified holders. The transactions are presented as reported sale notices for shares originally issued in a Private Placement dated 03/11/2020.
KYMR filed notices of proposed sales of Common Stock by affiliated holders, listing multiple transactions dated 04/14/2026 through 04/22/2026. The filing shows individual sales by insiders/holders including Bruce Booth and Atlas Venture Fund X, L.P., with examples of specific share amounts and dollar amounts.
Examples include Bruce Booth selling 4,159 shares on 04/14/2026 for $374,199.56 and Atlas Venture Fund X, L.P. selling 2,750 shares on 04/15/2026 for $247,765.57. The notice lists multiple small secondary sales by founders and venture funds across April 2026.
KYMR submitted a Form 144 reporting a proposed sale of 11,741 shares of Common Stock, dated 06/17/2026. The filing lists recent open-market dispositions by holders in April 2026.
The notice shows multiple prior sales, including Atlas Venture Fund X selling 2,750 shares for $247,765.57 on 04/15/2026 and Bruce Booth selling 5,900 shares for $530,746.25 on 04/22/2026. The filing identifies the securities as Common Stock and references stock-option-derived shares.
KYMR Rule 144 notice: Morgan Stanley Smith Barney LLC states 66,893 shares of common stock are to be sold following an exercise of stock options on 06/17/2026 for cash. The filing also lists multiple 10b5-1 sales by Jeremy Chadwick earlier in 2026, including a 91,250-share sale on 03/23/2026 for $7,063,733.26 and other transactions in March–May 2026.
Kymera Therapeutics, Inc. reported that Chief Operating Officer Jeremy Chadwick has communicated his intention to retire and submitted his resignation as COO on June 5, 2026. He will remain an employee of the company as an advisor until November 2026 to support the transition.
The company states that Mr. Chadwick resigned for personal reasons and that his decision was not the result of any disagreement with Kymera’s practices or policies. The filing is framed as an orderly leadership change with continued advisory involvement over several months.
Kymera Therapeutics, Inc. Chief Financial Officer Bruce N. Jacobs exercised stock options to acquire 12,653 shares of common stock at an exercise price of $2.08 per share. The corresponding stock option for 12,653 shares was fully exercised and now shows zero derivative shares remaining. Following this transaction, Jacobs holds 260,241 shares of Kymera Therapeutics common stock directly, with no related sale or tax-withholding disposition reported in this filing.
Kymera Therapeutics, Inc. Chief Operating Officer Jeremy G. Chadwick reported selling 17,184 shares of common stock in open-market transactions. The sales occurred on May 26–27, 2026 at weighted-average prices within ranges from about $77.99 to $82.15 per share. A footnote explains that the shares were required to be sold to cover tax withholding obligations tied to vesting restricted stock units and that these sales were automatic, not at his discretion. The transactions were effected under a Rule 10b5-1 trading plan dated December 10, 2025. Following the transactions, Chadwick directly holds 44,018 Kymera shares.